Inspiratory Flows and Volumes in Subjects with Cystic Fibrosis Using a New Dry Powder Inhaler Device

Mark R. Elkins1, Philip Robinson2, Sandra D. Anderson1, Clare P. Perry1, Evangelia Daviskas1, Brett Charlton*, 3
1 Royal Prince Alfred Hospital, Sydney, Australia
2 Murdock Children's Research Institute and University of Melbourne, Royal Children's Hospital, Melbourne, Australia
3 Pharmaxis Ltd, Sydney, Australia

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 3989
Abstract HTML Views: 2241
PDF Downloads: 842
Total Views/Downloads: 7072
Unique Statistics:

Full-Text HTML Views: 1992
Abstract HTML Views: 1307
PDF Downloads: 540
Total Views/Downloads: 3839

Creative Commons License
© Elkins et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at Pharmaxis Ltd., 20 Rodborough Road, Frenchs Forest NSW 2086, Australia; Fax: +61 2 9451 3622; E-mail:



Drug inhalation via a dry-powder inhaler (DPI) is a convenient, time efficient alternative to nebulizers in the treatment of cystic fibrosis (CF). Efficient drug administration via DPIs depends on the device resistance and adequate (≥ 45L/min) inspiratory flows and volumes generated by individuals. Dry-powder mannitol is delivered using a RS01 breath-actuated device developed by Plastiape, for Pharmaxis. The study aim was to determine in vivo if CF patients’ inspiratory flows and volumes are adequate to use the RS01 DPI device.

Materials and Methodology:

An open, non-interventional study; enrolled 25 CF subjects, aged ≥ 6 years with FEV1 ≥ 30 to < 90‰ predicted. Inspiratory flows and volumes were measured when subjects inhaled in a controlled manner through the RS01 device in series with a spirometer.


The mean inspiratory volume (IV) of CF subjects was 1.83L ± 0.97. Their achieved mean ± SD peak inspiratory flow (PIF) was 75.5 ± 27.2L/min. Twenty-three subjects (92%) achieved PIF of > 45L/min with the inhaler device; eighteen of those subjects (78%) had a baseline FEV1 of > 1L.


Use of the RS01 DPI device allowed adequate inspiratory flow and volume for dispersion of dry-powder mannitol in CF patients.

Keywords: : Clinical trials, cystic fibrosis, respiratory function tests, dry powder inhaler, high resistance inhaler, peak inspiratory flow..